NewAmsterdam Pharma Co. NV (NAMS) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$19.99

From 52W high−50.62%

Volume716512.00

Market cap$2.45B

P/E (TTM)—

P/S (TTM)343.6x

Div yield—

Key dataOct 19, 2026

Open

$19.99

From 52W high

−50.62%

Volume

716512.00

Market cap

$2.45B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−7.1x

P/E (TTM)

—

RSI (14)

36.9

MomentumView details →

1D Return

+3.23%

YTD Return

−41.76%

SummaryUpdated Jun 1, 2026

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Naarden, the Netherlands. The company went public in February 2021 and focuses on developing innovative treatments for metabolic diseases, particularly cardiovascular conditions related to cholesterol management. NewAmsterdam's primary focus is advancing its lead drug candidate through clinical trials to address unmet medical needs in cholesterol treatment and cardiovascular disease prevention.

Ask drillr about NewAmsterdam Pharma Co. NV →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−7.1x

EV/Sales

254.6x

P/S (TTM)

343.6x

P/B (TTM)

3.9x

ProfitabilityView details →

Gross Margin

92.15%

Net Margin

−3644.21%

EBITDA Margin

−3579.67%

ROE (TTM)

−41.10%

ROA (TTM)

−36.84%

Asset Turnover

0.01x

GrowthView details →

Revenue YoY

−88.87%

EPS YoY

−32.12%

FCF YoY

−15.62%

Revenue CAGR 3Y

−39.71%

EPS CAGR 3Y

+31.64%

EBITDA YoY

−32.54%

MomentumView details →

1D Return

+3.23%

YTD Return

−41.76%

1Y Return

−45.75%

RSI (14)

36.9

vs 50D SMA

−15.18%

vs 200D SMA

−32.78%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

9.03x

Quick Ratio

9.03x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.52

EPS Surprise

−7.90%

Beats (12Q)

2/12

Next Q EPS Est

−$0.45

Avg Surprise (4Q)

−15.06%

Rev Surprise

30.73%

Financials snapshotView financials →

Revenue (TTM)

7.12M

Net Income (TTM)

−259.50M

Op. CF (TTM)

−143.46M

Next earningsNov 4, 2026 →

Latest newsMore news →

NewAmsterdam Pharma dosed the first participant in its Phase 2b SPINOZA trial evaluating obicetrapib in adults with biomarker evidence of preclinical Alzheimer's disease.20d ago

The European Commission approved NewAmsterdam Pharma and Menarini Group's Ubeslo (obicetrapib monotherapy) and Evlarco (obicetrapib plus ezetimibe fixed-dose combination) in Europe.28d ago

Similar companies

ADMA Biologics, Inc.ADMA Beam Therapeutics Inc.BEAM Precigen, Inc.PGEN MBX Biosciences, Inc. Common StockMBX 东亚药业605177.SH Viridian Therapeutics, Inc.VRDN Find similar companies →

Latest newsMore news →

NewAmsterdam Pharma dosed the first participant in its Phase 2b SPINOZA trial evaluating obicetrapib in adults with biomarker evidence of preclinical Alzheimer's disease.20d ago The European Commission approved NewAmsterdam Pharma and Menarini Group's Ubeslo (obicetrapib monotherapy) and Evlarco (obicetrapib plus ezetimibe fixed-dose combination) in Europe.28d ago